APXZF (Carasent AB (publ)) 3-Year RORE % : -56.76% (As of Mar. 2026)


APXZF Carasent AB (publ) APXZF
80 GF Score
Price $0.15
GF Value $0.18
! 3 Warning Signs
View Full Analysis

What is Carasent AB (publ) 3-Year RORE %?

Carasent AB (publ) APXZF 80 3-Year RORE % is -56.76 as of Mar. 2026. GuruFocus rates APXZF with a GF Score™ of 80/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 605 Healthcare Providers & Services companies, Carasent AB (publ) ranks worse than 82.98% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Carasent AB (publ)'s 3-Year RORE % for the quarter that ended in Mar. 2026 was -56.76%.

The industry rank for Carasent AB (publ)'s 3-Year RORE % or its related term are showing as below:

APXZF's 3-Year RORE % is ranked worse than
82.98% of 605 companies
in the Healthcare Providers & Services industry
Industry Median: 0.74 vs APXZF: -56.76

Carasent AB (publ)  (OTCPK:APXZF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Carasent AB (publ) 3-Year RORE % Related Terms


Carasent AB (publ) 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Carasent AB (publ)'s 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carasent AB (publ) 3-Year RORE % Chart

Carasent AB (publ) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.02 -285.42 30.56 41.18 -46.70

Carasent AB (publ) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.71 -3.81 -18.57 -46.70 -56.76

APXZF vs VEEV, BTSG, TEM: 3-Year RORE % Comparison

For the Health Information Services subindustry, Carasent AB (publ)'s 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carasent AB (publ) 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Carasent AB (publ)'s 3-Year RORE % falls into.


APXZF
80GF Score
Carasent AB (publ) APXZF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carasent AB (publ) 3-Year RORE % Calculation

Carasent AB (publ)'s 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.062--0.064 )/( -0.048-0.174 )
=0.126/-0.222
=-56.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -56.76 mean?
Carasent AB (publ) (APXZF) has a 3-Year RORE % of -56.76 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Carasent AB (publ) and its competitors. According to the industry distribution chart, Carasent AB (publ) ranks #502 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 83%.
Is Carasent AB (publ)'s 3-Year RORE % too high?
Carasent AB (publ)'s current 3-Year RORE % is -56.76. Based on the distribution chart, Carasent AB (publ) ranks #502 out of 605 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #502 out of 605 companies for 3-Year RORE %. This places Carasent AB (publ) in the lower half of its industry. The industry median 3-Year RORE % is 0.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.74, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current 3-Year RORE % is -56.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current 3-Year RORE % of -56.76. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current 3-Year RORE % is -56.76. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current 3-Year RORE % is -56.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carasent AB (publ) (APXZF) Overvalued in 2026?

Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued. The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.

Key valuation signals for APXZF:

  • 3-Year RORE %: -56.76
  • GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carasent AB (publ) Business Description

Other Exchanges CARA:SwedenE0C:Germany
Address Nellickevagen 24C, Gothenburg, NOR, 412 63
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score

Get the complete analysis for APXZF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.18
GF Value